Which novel agents will benefit frail patients?

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Alessandra Larocca, City of Health and Science University Hospital,...

DART4MM study: Can daratumumab consolidation achieve MRD-negativity after frontline therapy?

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Alessandro Gozzetti,...

If maintenance after induction reduces therapy options at relapse, is it still worth it?

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Professor Graham Jackson,...

When is the optimal time to use bispecific antibodies in MM?

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to the steering committee member Hermann Einsele,...

Editorial theme | How multiple myeloma cells develop resistance to/escape from BCMA-directed novel agents

This article is the first in the series of our newest editorial theme of mechanisms of...

CAR-T versus bispecific antibodies and BiTEs in multiple myeloma

Chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (bsAbs)/bispecific T-cell engagers (BiTEs), even though they...

Advances of cell therapies in China: Reducing manufacturing time with FasT dual CAR T-cells

At the 3rd European CAR T-cell Meeting, held virtually in February 2021, Jianxiang Wang presented...

What is there to know about the EBMT GoCART coalition?

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Sofie Rosanne Terwel, EBMT GoCART, Leiden, NL. We asked, What is...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

Can lenalidomide maintenance be given to patients with MM and COVID-19 infection?

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University,...

How do I manage the risk of infection in patients treated with immunotherapies?

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer...

Mortality risk and clinical outcomes in patients with MM admitted to hospital with SARS-CoV-2/COVID-19 infection

In a multi-center case series, Joaquin Martinez-Lopez and colleagues presented data...